Table 1 Demographic and clinical characteristics of patients
From: Real-world evidence of fremanezumab for treating migraine in Japan: a retrospective study
Characteristics | EM (n = 19) | CM (n = 10) | All (n = 29) |
|---|---|---|---|
Age, years | 50.7 ± 11.2 | 40.5 ± 8.6 | 47.2 ± 12.4 |
Sex, female | 15 (78.9) | 8 (80.0) | 23 (79.3) |
BMI, kg/m2 | 21.4 ± 4.0 | 23.6 ± 7.2 | 22.2 ± 5.3 |
Onset age, years | 24.4 ± 11.2 | 15.7 ± 9.4 | 21.4 ± 11.3 |
Disease history, years | 26.3 ± 14.2 | 24.8 ± 13.3 | 25.8 ± 13.7 |
NRS | 5.6 ± 1.6 | 5.9 ± 1.1 | 5.7 ± 1.4 |
Migraine characteristics | |||
Unilateral pain | 15 (78.9) | 6 (60.0) | 21 (72.4) |
Pulsating pain | 11 (57.9) | 6 (60.0) | 17 (58.6) |
Aggravation by routine physical activity | 15 (78.9) | 10 (100.0) | 25 (86.2) |
MMD | 8.8 ± 2.8 | 19.7 ± 7.6 | 12.6 ± 7.2 |
MHD | 10.5 ± 2.5 | 22.7 ± 5.9 | 14.7 ± 7.1 |
AMD | 7.0 ± 3.9 | 17.0 ± 7.8 | 10.5 ± 7.3 |
Medication-overuse headache | 0 (0.0) | 7 (70.0) | 7 (24.1) |
Aura | 3 (15.8) | 1 (10.0) | 4 (13.8) |
Associated symptoms | |||
Photophobia | 12 (63.2) | 7 (70.0) | 19 (65.5) |
Phonophobia | 16 (84.2) | 7 (70.0) | 23 (79.3) |
Nausea/vomiting | 13 (68.4) | 7 (70.0) | 20 (69.0) |
Psychiatric past history | 5 (26.3) | 5 (50.0) | 10 (34.5) |
GAD-7 ≥ 5 | 7 (36.8) | 6 (60.0) | 13 (44.8) |
GAD-7 ≥ 10 | 1 (5.3) | 3 (30.0) | 4 (13.8) |
PHQ-9 ≥ 5 | 9 (47.4) | 8 (80.0) | 17 (58.6) |
PHQ-9 ≥ 10 | 2 (10.5) | 3 (30.0) | 5 (17.2) |
Family history of headache | 12 (63.2) | 7 (70.0) | 19 (65.5) |